drugset / Trial / NCT01226602

Study to Assess the Effect of Ticagrelor on Coronary Blood Flow in Healthy Male Subjects.

NCT01226602

Phase 1 Completed 39 enrolled AstraZeneca
RandomizedCrossoverTriple-blindTreatment

Summary

The purpose of this study is to determine if Ticagrelor increases the Adenosin induced coronary blood flow velocity.

Timeline

Start
2010-12
Primary completion
2011-04
Completion
2011-04

Drugs

EvaluationDrugModalityDoseRoute
Subject Ticagrelor Small molecule 180 mg

Indications

No indication recorded.